Shots:
- The P-III CLL14 trial assessing the efficacy & safety of a combined regimen of Venclyxto/Venclexta + obinutuzumab vs obinutuzumab and chlorambucil in 432 patients with previously untreated CLL
- Results: @median follow-up of 52.4 mos., PFS rate (74% vs 35.4%) after 1 yr. fixed-duration treatment, 67% reduction in risk of disease progression or death; OS rate (85.4% vs 83.1%), no new safety signals were identified, improvement in PFS was observed in all clinical & biological risk groups, includes TP53 mutation, 17p deletion & unmutated IGHV status
- Additionally, 26.9% of patients with Venclyxto/Venclexta-based combination still had undetectable MRD compared to 3.2% of patients with obinutuzumab + chlorambucil arm @ 30 mos.
Click here to read full press release/ article | Ref: Abbvie | Image: Wall Street Journal
The post AbbVie Reports Results of Four-Year Follow-Up Analysis in P-III CLL14 Trial for Venclyxto/Venclexta to Treat Chronic Lymphocytic Leukemia first appeared on PharmaShots.
